Data as of Sep 16
| +0.0701 / +2.00%|
The 1 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 10.00, with a high estimate of 10.00 and a low estimate of 10.00. The median estimate represents a +180.11% increase from the last price of 3.57.
The current consensus among 1 polled investment analysts is to Buy stock in Rosetta Genomics Ltd. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.